Tropisetron HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100896

CAS#: 105826-92-4 (HCl)

Description: Tropisetron, also known as ICS-205930, is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia. The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the U.S. It is also available from Novell Pharmaceutical Laboratories and marketed in several Asian countries as Setrovel.


Chemical Structure

img
Tropisetron HCl
CAS# 105826-92-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 100896
Name: Tropisetron HCl
CAS#: 105826-92-4 (HCl)
Chemical Formula: C18H23ClN2O2
Exact Mass: 0.00
Molecular Weight: 334.840
Elemental Analysis: C, 64.57; H, 6.92; Cl, 10.59; N, 8.37; O, 9.56

Price and Availability

Size Price Availability Quantity
5g USD 350
10g USD 650
20g USD 1050
50g USD 2250
100g USD 3950
200g USD 7450 2 Weeks
Bulk inquiry

Related CAS #: 89565-68-4 (free base)   105826-92-4 (HCl)    

Synonym: ICS-205930; ICS 205930; ICS205930; ICS 205-930; ICS-205-930; Tropisetron; Tropisetron HCl; Brand name Navoban.

IUPAC/Chemical Name: (1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1-methyl-1H-indole-3-carboxylate hydrochloride

InChi Key: MUIOOVJZGDYUGE-LIWIJTDLSA-N

InChi Code: InChI=1S/C18H22N2O2.ClH/c1-19-11-16(15-5-3-4-6-17(15)19)18(21)22-14-9-12-7-8-13(10-14)20(12)2;/h3-6,11-14H,7-10H2,1-2H3;1H/t12-,13+,14?;

SMILES Code: O=C(C1=CN(C)C2=C1C=CC=C2)OC3C[C@@H](N4C)CC[C@H]4C3.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 105826-92-4 (Tropisetron HCl) 89565-68-4 (Tropisetron free base).  

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 334.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 2010 May;27(3):219-25. Epub 2010 Mar 2. PubMed PMID: 20197557.

2: Marcus DA. Fibromyalgia: diagnosis and treatment options. Gend Med. 2009;6 Suppl 2:139-51. PubMed PMID: 19406366.

3: Fujii Y. Current management of vomiting after tonsillectomy in children. Curr Drug Saf. 2009 Jan;4(1):62-73. Review. PubMed PMID: 19149526.

4: Fujii Y. The benefits and risks of different therapies in preventing postoperative nausea and vomiting in patients undergoing thyroid surgery. Curr Drug Saf. 2008 Jan;3(1):27-34. Review. PubMed PMID: 18690978.

5: Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther. 2006 Apr 1;3(3):140-2. PubMed PMID: 18632487.

6: Di Maio M, Gallo C, Perrone F. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy]. Tumori. 2008 Mar-Apr;94(2):suppl 14-22. Italian. PubMed PMID: 18564621.

7: Harten P. [Fibromyalgia syndrome: new developments in pharmacotherapy]. Z Rheumatol. 2008 Feb;67(1):75-82. Review. German. PubMed PMID: 17924124.

8: Leung AK, Robson WL. Acute gastroenteritis in children: role of anti-emetic medication for gastroenteritis-related vomiting. Paediatr Drugs. 2007;9(3):175-84. Review. PubMed PMID: 17523698.

9: Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007 Sep;15(9):1023-33. Epub 2007 Jan 5. PubMed PMID: 17205281.

10: Neufeld SM, Newburn-Cook CV. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis. J Neurosurg Anesthesiol. 2007 Jan;19(1):10-7. Review. PubMed PMID: 17198095.